Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 safety and efficacy study evaluating CTX120 in relapsed or refractory multiple myeloma has been terminated. No results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CTX120

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED